Here are six observations:
1. The new treatment, Pip6a-PMO, involves peptide Pip6a delivering the splice-switching oligonucleotide.
2. Pip6a has the ability to deliver splice-switching oligonucleotides to many tissues in the body, even into the brain and spinal cords.
3. After injecting SMA-ridden young mice with Pip6a-PMO, they became heavier and grew faster than untreated mice.
4. The treated mice lived longer than untreated mice. One dose of 10 microgrammes per gram of weight of Pip6a-PMO allowed the young mice to live for a median 167 days, compared to 12 days for untreated mice.
5. Two doses of Pip6a-PMO resulted in mice living at least 200 days with a median survival of 457 days. This reflects a survival period that is 38 times longer than untreated mice.
6. The researchers plan to conduct a two-year study involving human patients, which is set to commence in 2017.
More articles on spine:
Elderly patients undergoing spinal curvature surgery jumps 107%: 5 things to know
The Leading Physicians of the World highlights Dr. Safdar Khan — 5 highlights
How do cage angle & surgical technique impact segmental lordosis? 6 insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
